The Safety and Efficiency of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.
The Safety and Efficiency of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.
Based on the development of new tools, including drug coated balloon, paclitaxel eluting
 stent, interwoven stents, debulking tools, More and more acute or subacute thromboembolic
 occlusions of lower extremity included stage IIb were treated with endovascular procedures.
 Most guidelines suggests only stage I and stage IIa lesions are suitable for endovascular
 treatments. Therefore, a well-designed real-world study that track the safety and clinical
 relevant outcomes, are required to determine the optimal therapies for patients with acute or
 subacute thromboembolic occlusions of lower extremity.
According to the Trans-Atlantic Inter-Society Consensus (TASC) II guidelines, acute arterial
 occlusion which in stage IIb was recommended for thrombectomy. However, with the development
 of new tools, including drug coated balloon, paclitaxel eluting stent, interwoven stents,
 debulking tools, stage IIb patients and some subacute thromboembolic lesions were also
 effective in some retrospective studies.

 Despite The shift of Endovascular-first strategy has been documented in recent literature.
 There still lack evidence to support either approach have a significant advantage over the
 thrombectomy. And stage IIb lesions and subacute lesions are often excluded in prospective
 clinical trials. Therefore, a well-designed real-world study that track the safety and
 clinical relevant outcomes, are required to determine the optimal therapies for patients with
 acute or subacute thromboembolic occlusions of lower extremity.
Inclusion Criteria:

 1. Patients over 18 years old.

 2. acute or subacute limb ischemia patients with Rutherford classification stage range
 from I to IIb.

 3. Patients with Rutherford classification range from 3 to 5.

 4. The guide wire should pass through the lesion of femoropopliteal artery, and further
 endovascular treatment is performed. In this study, we did not limit the methods of
 the guide wire passing through the target lesion. After the angiography and/or
 performed under digital subtraction angiography(DSA) which confirmed the existing of
 thrombus, and which is related to occlusions of lower extremity or in-stent
 restenosis.

 5. Pharmacomechanical thrombectomy (PMT) and/or catheter-directed thrombolysis (CDT) was
 or were used for thrombus removal.

 6. The lower extremity artery needs to have a healthy runoff of no less than 10 cm above
 the ankle, and at least one healthy dorsalis pedis artery, medial or lateral plantar
 artery connected with the digital artery below the ankle.

 7. Informed consent signed by patients.

 Exclusion Criteria:

 1. acute or subacute limb ischemia patients with Rutherford classification stage III.

 2. Patients with thromboangiitis obliterans.

 3. Patients with failure of endovascular treatment, and transfer to open surgery or
 hybrid operation.

 4. People with stroke, cerebral hemorrhage, gastrointestinal bleeding or myocardial
 infarction and so on in the past 3 months.

 5. Patients with known allergy to heparin, low molecular weight heparin and contrast
 agents.

 6. Patients with high bleeding risk.

 7. Women during pregnancy and lactation.

 8. Patients with other diseases that may lead to difficulties in the trial or
 significantly shorten the life expectancy (< 2 years), such as tumors, severe liver
 disease, cardiac insufficiency.

 9. Patients who have been enrolled in other clinical trials in the past 3 months.

 10. Patients who are unwilling or refuse to sign the informed consent form.

 -